极光wpn

Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan.
read more ...

Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration has been announced.
read more ...

Corporate Governance Report has now been updated.
read more ...

Disposal of Treasury Shares as Restricted Share-Based Remuneration has been announced.
read more ...

ASCO 2023 Highlight materials are now available.
read more ...

Convocation Notice of the 15th Ordinary General Meeting of Shareholders is now available.
read more ...

FY2023 Q4 financial results are now available.
read more ...

2023.07.27	Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
2023.07.22	Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan
2023.07.21	Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients
2023.07.10	Daiichi Sankyo Announces Participation in AMR Action Fund
2023.07.07	EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer
2023.07.02	Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
2023.06.29	Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT
2023.06.26	Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Corona Virus Vaccine

2023.06.15	Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 13th Annual Clinical Pharmacology Research Award
2023.06.12	R&D Activities for COVID-19 Vaccines and Therapeutics
2023.04.22	Daiichi Sankyo Announces Collaborative Research with DNDi on Drugs for Neglected Tropical Diseases
2023.04.13	Our Company’s Efforts to Limit the Spread of the Virus that Causes COVID-19

Who We Are

Our People

Partnerships

国外伋理服务器ip免费

Daiichi Sankyo Library

Our Approach

Pipeline

Open Innovation

TaNeDS Global

Media Relations

Investor Relations

CSR TOP

Responsible Corporate Activities

CSR Activities in Six Priority Areas

在线伋理服务器免费网页版

香港伋理服务器ip免费

Reports